Related Experiment Video
Updated: Apr 1, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.4K
A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients
Jiangnan Zhao1,2,3, Zijin Wang4,5, Manyu Xiao4,5
1Department of Respiratory and Critical Care Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
EMBO Molecular Medicine
|March 30, 2026
Summary
Predicting lung squamous cell carcinoma (LUSC) treatment response is crucial. Higher baseline monocyte levels in blood and tumors indicate better immunochemotherapy (IC) response in LUSC patients.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Lung squamous cell carcinoma (LUSC) is a major cause of cancer mortality globally.
- Current first-line immunochemotherapy (IC) for advanced LUSC lacks reliable response predictors.
Purpose of the Study:
- To identify predictive biomarkers for immunochemotherapy (IC) response in lung squamous cell carcinoma (LUSC).
Main Methods:
- Single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples.
- Validation using complete blood count and multiplex immunofluorescence in independent cohorts.
Main Results:
- Responders to IC showed significantly higher baseline levels of peripheral blood monocytes, tumor-infiltrating classical monocytes, and APOBEC3A+ monocytes compared to non-responders.
- These monocyte-related parameters were validated across different patient cohorts and analytical methods.
Conclusions:
- Monocyte counts and characteristics serve as accessible indicators linking systemic immunity to the tumor microenvironment.
- These findings offer potential for predicting immunochemotherapy (IC) responsiveness in lung squamous cell carcinoma (LUSC) patients.
